Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us.
A weight-loss injection with results on par with bariatric surgery? With retatrutide, that is not an exaggeration.
Although it’s not FDA approved yet, retatrutide is one of the most talked-about medications coming down the line. In this episode, I’m unpacking Eli Lilly’s new “triple agonist” medication, which targets three different pathways: GLP-1, GIP, and glucagon.
We’ll talk about how retatrutide may help curb appetite, support insulin sensitivity, increase energy expenditure, and accelerate fat metabolism.
I’ll also walk you through the standout clinical trial numbers behind the hype and take an honest look at tolerability, discontinuation rates, and side effects, including nausea, diarrhoea, and vomiting, so you can understand the full picture.
References
Harvard Study: Benefits of Micro Walks
Cali Boyz Burritos
Secure your spot for the September round of The 30/30 Program now (spaces limited).
Subscribe to my Youtube channel
All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast.
If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com
Not Sure Where to Start With the Podcast? I’ve Got You.
Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.
Support the show
